Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals (ADXS) is a clinical-stage biotech company pioneering novel cancer immunotherapies and small molecule treatments targeting rare tumors and aggressive cancers. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases, trial result announcements, and expert analyses of ADXS's proprietary bacterial-based immunotherapy platform. Key focus areas include advancements in modifying the tumor microenvironment, progress across the company's oncology pipeline, and collaborations advancing next-generation cancer therapies.
Users can expect comprehensive coverage of:
• Clinical trial updates for immunotherapy candidates
• Strategic partnership announcements with biopharma leaders
• Regulatory developments across global markets
• Scientific presentations at major oncology conferences
Bookmark this page for verified updates on Ayala Pharm's progress in developing treatments that harness the immune system to combat challenging cancers. Check regularly for new insights into their dual-platform approach combining bacterial vectors and targeted small molecules.
Advaxis, Inc. (Nasdaq: ADXS) announced a definitive agreement with institutional investors for the purchase of 17,577,400 shares of common stock, 7,671,937 pre-funded warrants, and registered warrants for 11,244,135 shares, generating total proceeds of approximately $14 million. The offering is priced at $0.7921 per share and $0.7911 per pre-funded warrant. The funds will support research initiatives, including the ADXS-HOT program, and potential investments in other businesses. The offering follows SEC regulations and is executed by A.G.P./Alliance Global Partners.
Advaxis (ADXS) has collaborated with Precision for Medicine to develop a novel flow cytometry assay to evaluate PD-1 expression as a pharmacodynamic biomarker in T cells during PD-1 blockade. The assay can determine PD-1 expression independent of receptor status, including both free and drug-bound PD-1. Data presented at the AACR Annual Meeting 2021 indicate that patients treated with ADXS-503 in combination with KEYTRUDA displayed significant activation of immune responses, offering insights into enhanced treatment strategies in non-small cell lung cancer (NSCLC). The ongoing Phase 1/2 trial aims to establish the safety and clinical activity of ADXS-503.
Advaxis, Inc. announced a partnership with Columbia University to initiate a Phase 1 clinical study of ADXS-504 in patients with biochemically recurrent prostate cancer, anticipated to begin in Q2 2021. The trial will evaluate the safety and tolerability of this novel neoantigen immunotherapy targeting multiple tumor antigens in 9-18 patients. Given the rising prostate cancer diagnoses in 2021, this study aims to explore new immune-based treatment options. Notably, previous studies showed promise for ADXS-PSA in advanced prostate cancer, indicating potential for ADXS-504.
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotech firm, will have its CEO, Kenneth A. Berlin, present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Berlin's presentation is scheduled for 2:30 PM ET on March 24. Interested investors can view the presentation and request meetings via registration at the conference's website. Advaxis specializes in immunotherapy products utilizing bioengineered Listeria monocytogenes for enhanced anti-tumor T-cell immunity. For more details, visit advaxis.com.
Advaxis, Inc. (Nasdaq: ADXS) reported promising results from its ongoing Phase 1/2 trial of ADXS-503 in non-small cell lung cancer (NSCLC), with a disease control rate of 67% and an overall response rate of 17% among the first six patients who had prior progression on KEYTRUDA®. The company recently closed a $9.2 million public offering, strengthening its balance sheet to support continued clinical development. Research and development expenses were reduced to $2.6 million, allowing the company to maintain a solid cash position of $33.3 million through May 2022.
Advaxis (Nasdaq: ADXS) announced a collaboration with Precision for Medicine to present data at the AACR Annual Meeting 2021, scheduled from April 10-15. The presentation will focus on a novel flow immunophenotyping assay for evaluating PD-1 expression during pembrolizumab treatment and its correlation with T cell populations in the ongoing ADXS-503 trial. The poster, titled Evaluation of total PD-1 expression using multi-color flow cytometry, highlights immunotherapy advancements in metastatic non-small cell lung cancer. Full details will be available on the AACR website starting April 10.
Advaxis, a biotechnology company focused on immunotherapy, is advancing its ADXS-503 program in non-small cell lung cancer (NSCLC). Recent clinical data showed a 67% disease control rate and 17% overall response rate in patients previously treated with KEYTRUDA®. The company strengthened its financial position with a $9.2 million public offering and initiated new clinical arms for ADXS-503. For the fiscal year ending October 31, 2020, Advaxis reported a net loss of $26.5 million and reduced R&D expenses by $11.1 million.
Advaxis, Inc. (NASDAQ: ADXS) announced a milestone payment for its licensing agreement with OS Therapies for ADXS31-164 (OST-HER2) aimed at treating osteosarcoma. OS Therapies, in collaboration with the Children’s Oncology Group, will conduct a clinical study funded through secured financing. Advaxis will receive additional milestone payments and royalties on future sales. The treatment has potential benefits for children with limited options, building on prior successful trials in canines and humans. Advaxis continues to focus on its ADXS-HOT neoantigen program.
Advaxis, Inc. (Nasdaq: ADXS) has received approval to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective December 24, 2020. This decision follows the company's stock trading below the minimum bid price required. Advaxis has been granted an additional 180-day period to meet the $1.00 bid price requirement, expiring June 21, 2021. If the stock does not regain compliance, it may face delisting, although an appeal option is available. Notably, the company plans to consider a reverse stock split if necessary, to meet the bid price requirement.
Advaxis, Inc. (ADXS) has successfully closed an underwritten public offering of 26,666,666 common shares and warrants for 13,333,333 shares, raising approximately $9.2 million at $0.30 per share. This includes an overallotment of 3,999,999 shares and 1,999,999 warrants. The funds will support ongoing R&D, particularly the ADXS-HOT program, and may also be used for potential acquisitions or investments. The offering was executed under an effective shelf registration statement.
